Publication Listing for the MeSH term drug therapy. Found 408 abstracts
no paginationCohen EE, Soulieres D, Le Tourneau C, Dinis J, Licitra L, Ahn MJ, Soria A, Machiels JP, Mach N, Mehra R, Burtness B, Zhang P, Cheng J, Swaby RF, Harrington KJ. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. Lancet (London, England). 2019 Jan 12;393(10167):156-67. |
Dash PK, Kaminski R, Bella R, Su H, Mathews S, Ahooyi TM, Chen C, Mancuso P, Sariyer R, Ferrante P, Donadoni M, Robinson JA, Sillman B, Lin Z, Hilaire JR, Banoub M, Elango M, Gautam N, Mosley RL, Poluektova LY, McMillan J, Bade AN, Gorantla S, Sariyer IK, Burdo TH, Young WB, Amini S, Gordon J, Jacobson JM, Edagwa B, Khalili K, Gendelman HE. Sequential LASER ART and CRISPR Treatments Eliminate HIV-1 in a Subset of Infected Humanized Mice. Nat Commun. 2019 Jul 02;10(1):2753. PMCID: PMC6606613 |
Golan T, Hammel P, Reni M, Van Cutsem E, Macarulla T, Hall MJ, Park JO, Hochhauser D, Arnold D, Oh DY, Reinacher-Schick A, Tortora G, Algul H, O'Reilly EM, McGuinness D, Cui KY, Schlienger K, Locker GY, Kindler HL. Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer. The New England journal of medicine. 2019 Jul 25;381(4):317-27. PMCID: PMC6810605 |
Hellmann MD, Paz-Ares L, Bernabe Caro R, Zurawski B, Kim SW, Carcereny Costa E, Park K, Alexandru A, Lupinacci L, de la Mora Jimenez E, Sakai H, Albert I, Vergnenegre A, Peters S, Syrigos K, Barlesi F, Reck M, Borghaei H, Brahmer JR, O'Byrne KJ, Geese WJ, Bhagavatheeswaran P, Rabindran SK, Kasinathan RS, Nathan FE, Ramalingam SS. Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer. The New England journal of medicine. 2019 Sep 28;381(21):2020-31. |
Rini BI, Plimack ER, Stus V, Gafanov R, Hawkins R, Nosov D, Pouliot F, Alekseev B, Soulieres D, Melichar B, Vynnychenko I, Kryzhanivska A, Bondarenko I, Azevedo SJ, Borchiellini D, Szczylik C, Markus M, McDermott RS, Bedke J, Tartas S, Chang YH, Tamada S, Shou Q, Perini RF, Chen M, Atkins MB, Powles T. Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. The New England journal of medicine. 2019 Mar 21;380(12):1116-27. |
Tomitaka A, Kaushik A, Kevadiya BD, Mukadam I, Gendelman HE, Khalili K, Liu G, Nair M. Surface-engineered multimodal magnetic nanoparticles to manage CNS diseases. Drug discovery today. 2019 Mar;24(3):873-82. |
Voss MH, Bhatt RS, Vogelzang NJ, Fishman M, Alter RS, Rini BI, Beck JT, Joshi M, Hauke R, Atkins MB, Burgess E, Logan TF, Shaffer D, Parikh R, Moazzam N, Zhang X, Glasser C, Sherman ML, Plimack ER. A phase 2, randomized trial evaluating the combination of dalantercept plus axitinib in patients with advanced clear cell renal cell carcinoma. Cancer. 2019 Apr 05;125(14):2400-8. PMCID: PMC6602847 |
Amin A, Plimack ER, Ernstoff MS, Lewis LD, Bauer TM, McDermott DF, Carducci M, Kollmannsberger C, Rini BI, Heng DY, Knox J, Voss MH, Spratlin J, Berghorn E, Yang L, Hammers HJ. Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study. Journal for immunotherapy of cancer. 2018 Oct 22;6(1):109. PMCID: PMC6196426 |
Drilon A, Laetsch TW, Kummar S, DuBois SG, Lassen UN, Demetri GD, Nathenson M, Doebele RC, Farago AF, Pappo AS, Turpin B, Dowlati A, Brose MS, Mascarenhas L, Federman N, Berlin J, El-Deiry WS, Baik C, Deeken J, Boni V, Nagasubramanian R, Taylor M, Rudzinski ER, Meric-Bernstam F, Sohal DP, Ma PC, Raez LE, Hechtman JF, Benayed R, Ladanyi M, Tuch BB, Ebata K, Cruickshank S, Ku NC, Cox MC, Hawkins DS, Hong DS, Hyman DM. Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children. The New England journal of medicine. 2018 Feb 22;378(8):731-9. PMCID: PMC5857389 |
Gerson JN, Ramamurthy C, Borghaei H. Managing adverse effects of immunotherapy. Clinical advances in hematology & oncology : H&O. 2018 May;16(5):364-74. PMCID: Review |
Gettinger S, Hellmann MD, Chow LQ, Borghaei H, Antonia S, Brahmer JR, Goldman JW, Gerber DE, Juergens RA, Shepherd FA, Laurie SA, Young TC, Li X, Geese WJ, Rizvi N. Nivolumab Plus Erlotinib in Patients With EGFR-Mutant Advanced NSCLC. J Thorac Oncol. 2018 Sep;13(9):1363-72. |
Geynisman DM, Meeker CR, Doyle JL, Handorf EA, Bilusic M, Plimack ER, Wong YN. Provider and patient burdens of obtaining oral anticancer medications. The American journal of managed care. 2018 Apr;24(4):e128-e133. |
Ghatalia P, Zibelman MR, Geynisman DM, Plimack ER. Evolving landscape of the treatment of metastatic clear cell renal cell carcinoma. Clinical advances in hematology & oncology : H&O. 2018 Oct;16(10):677-86. |
Hahn NM, Necchi A, Loriot Y, Powles T, Plimack ER, Sonpavde G, Roupret M, Kamat AM. Role of Checkpoint Inhibition in Localized Bladder Cancer. European urology oncology. 2018 Aug;1(3):190-8. |
Harshman LC, Chen YH, Liu G, Carducci MA, Jarrard D, Dreicer R, Hahn N, Garcia JA, Hussain M, Shevrin D, Eisenberger M, Kohli M, Plimack ER, Cooney M, Vogelzang NJ, Picus J, Dipaola R, Sweeney CJ. Seven-Month Prostate-Specific Antigen Is Prognostic in Metastatic Hormone-Sensitive Prostate Cancer Treated With Androgen Deprivation With or Without Docetaxel. J Clin Oncol. 2018 Feb;36(4):376-82. PMCID: PMC5805480 |
Jung K, Park JC, Kang H, Brandes JC. Androgen deprivation therapy is associated with decreased second primary lung cancer risk in the United States veterans with prostate cancer. Epidemiology and health. 2018 Aug;40:e2018040. PMCID: PMC6232654 |
Kluetz PG, Kanapuru B, Lemery S, Johnson LL, Fiero MH, Arscott K, Barbachano Y, Basch E, Campbell M, Cappelleri JC, Cella D, Cleeland C, Coens C, Daniels S, Denlinger CS, Fairclough DL, Hillard JR, Minasian L, Mitchell SA, O'Connor D, Patel S, Rubin EH, Ryden A, Soltys K, Sridhara R, Thanarajasingam G, Velikova G, Coons SJ. Informing the Tolerability of Cancer Treatments Using Patient-Reported Outcome Measures: Summary of an FDA and Critical Path Institute Workshop. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research. 2018 Jun;21(6):742-7. |
Kluetz PG, Kanapuru B, Lemery S, Johnson LL, Fiero MH, Arscott K, Barbachano Y, Basch E, Campbell M, Cappelleri JC, Cella D, Cleeland C, Coens C, Daniels S, Denlinger CS, Fairclough DL, Hillard JR, Minasian L, Mitchell SA, O'Connor D, Patel S, Rubin EH, Ryden A, Soltys K, Sridhara R, Thanarajasingam G, Velikova G, Coons SJ. Informing the Tolerability of Cancer Treatments Using Patient-Reported Outcome Measures: Summary of an FDA and Critical Path Institute Workshop. Value Health. 2018 Jun;21(6):742-7. |
Kyriakopoulos CE, Chen YH, Carducci MA, Liu G, Jarrard DF, Hahn NM, Shevrin DH, Dreicer R, Hussain M, Eisenberger M, Kohli M, Plimack ER, Vogelzang NJ, Picus J, Cooney MM, Garcia JA, DiPaola RS, Sweeney CJ. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial. J Clin Oncol. 2018 Apr 10;36(11):1080-7. PMCID: PMC5891129 |
Li M, Sohn JA, Seeger C. Distribution of Hepatitis B Virus Nuclear DNA. J Virol. 2018 Jan;92(1). PMCID: PMC5730781 |
MeSH cloud from publications including the MeSH term drug therapy
drug therapy
therapeutic use
Male
Aged
pathology
administration & dosage
Middle Aged
adverse effects
Antineoplastic Agents
Female
Adult
Treatment Outcome
Antineoplastic Combined Chemotherapy Protocols
80 and over Aged
genetics
antagonists & inhibitors
mortality
Kidney Neoplasms
Prostatic Neoplasms
Neoplasm Metastasis
therapy
Neoplasms
Programmed Cell Death 1 Receptor
Docetaxel
Time Factors
Nivolumab
Retrospective Studies
Kaplan-Meier Estimate
United States
immunology
Androgen Antagonists
Lung Neoplasms
metabolism
B7-H1 Antigen
Monoclonal Antibodies-Humanized
pharmacology
tolerability
oncology
Progression-Free Survival
secondary
Hormone-Dependent Neoplasms
CTLA-4 Antigen
Non-Small-Cell Lung Carcinoma
Critical Pathways
epidemiology
Surveys and Questionnaires
prevention & control
drug safety
Drug-Related Side Effects and Adverse Reactions
patient-reported outcomes
Medical Oncology
United States Food and Drug Administration
Immunological Antineoplastic Agents
virology
Patient Reported Outcome Measures
Pro-ctcae
Ipilimumab
physiology
Pyrimidines
statistics & numerical data
methods
Renal Cell Carcinoma
Sunitinib
Viral DNA
chemistry
Monoclonal Antibodies
Duck Hepatitis B Virus
Drug Delivery Systems
Transitional Cell Carcinoma
pd-1
Cell Cycle Checkpoints
Preschool Child
Local Neoplasm Recurrence
Infant
HIV-1
Intravenous Administration
pd-l1
Hepatocytes
Health Services Accessibility
Piperazines
Veterans
Pharmaceutical Services Insurance
Metastatic renal cell carcinoma
Pancreatic Neoplasms
Hematologic Neoplasms
Pazopanib
Registries
Young Adult
chemotherapy
Follow-Up Studies
Randomized Controlled Trials as Topic
angiogenesis
etiology
Anti-HIV Agents
Nanoparticles
ctla-4
Preclinical Drug Evaluation
drug effects
Circular DNA
Dermatitis
adverse
viral persistence
Neoplastic Gene Expression Regulation
Adenocarcinoma
Oral Administration
Hepatitis B virus
Double-Blind Method
Phthalazines
Cell Division
Urinary Bladder Neoplasms
hepatitis B virus
Sulfonamides
effects
Methotrexate
Adolescent
Chronic Hepatitis B
Protein Kinase Inhibitors
Gene Editing
BRCA2 Genes
antiangiogenic agents
Treatment
Androgen antagonists
Fluorescence In Situ Hybridization
BRCA1 Genes
Colitis
Pyrazoles
Germ-Line Mutation
Cetuximab
Neoplasm Proteins
Surface Properties
Immunotherapy
Antiangiogenic
Single-Blind Method
Hormones
Disease-Free Survival
Bladder cancer
Erlotinib Hydrochloride
Prostate-Specific Antigen
Deductibles and Coinsurance
Virus Replication
Erlotinib
Disease Management
EGFR-mutant NSCLC
Second Primary Neoplasms
Axitinib
randomized controlled trial
Medical Assistance
Survival Rate
Central Nervous System Diseases
Mice